Serum fatty acid binding protein 4 levels are associated with abdominal aortic calcification in peritoneal dialysis patients

References

• Budoff MJ, Rader DJ, Reilly MP, et al. Relationship of estimated GFR and coronary artery calcification in the CRIC (chronic renal insufficiency cohort) study. Am J Kidney Dis. 2011;58(4):519–526.
   PubMed Web of Science ®Google Scholar
• Kim JK, Park HC, Song YR, et al. Effects of excessive body fat accumulation on long-term outcomes during peritoneal dialysis. Perit Dial Int. 2019;39(3):268–275.
   PubMed Web of Science ®Google Scholar
• Rincón BA, Bucalo L, Abad ES, et al. Fat tissue and inflammation in patients undergoing peritoneal dialysis. Clin Kidney J. 2016;9(3):374–380.
   PubMed Web of Science ®Google Scholar
• Axelsson J, Carrero JJ, Avesani CM, et al. Adipokine signaling in the peritoneal dialysis patient. Contrib Nephrol. 2006;150:166–173.
   PubMed Web of Science ®Google Scholar
• Shi M, Ma L, Fu P. Role of fatty acid binding protein 4 (FABP4) in kidney disease. Curr Med Chem. 2020;27(22):3657–3664.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Calvo R, Girona J, Alegret JM, et al. Role of the fatty acid-binding protein 4 in heart failure and cardiovascular disease. J Endocrinol. 2017;233(3):R173–R184.
   PubMed Web of Science ®Google Scholar
• Xu A, Wang Y, Xu JY, et al. Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome. Clin Chem. 2006;52(3):405–413.
   PubMed Web of Science ®Google Scholar
• Nakamura R, Okura T, Fujioka Y, et al. Serum fatty acid-binding protein 4 (FABP4) concentration is associated with insulin resistance in peripheral tissues, a clinical study. PLoS One. 2017;12(6):e179737.
   Web of Science ®Google Scholar
• Wang CH, Lai YH, Lin YL, et al. Increased serum leptin level predicts bone mineral density in hemodialysis patients. Int J Endocrinol. 2020;2020:1–7.
   Web of Science ®Google Scholar
• Okuno S, Ishimura E, Norimine K, et al. Serum adiponectin and bone mineral density in male hemodialysis patients. Osteoporos Int. 2012;23(7):2027–2035.
   PubMed Web of Science ®Google Scholar
• Zhang C, Chiu KY, Chan B, et al. Knocking out or pharmaceutical inhibition of fatty acid binding protein 4 (FABP4) alleviates osteoarthritis induced by high-fat diet in mice. Osteoarthritis Cartilage. 2018;26(6):824–833.
   PubMed Web of Science ®Google Scholar
• Kauppila LI, Polak JF, Cupples LA, et al. New indices to classify location, severity and progression of calcific lesions in the abdominal aorta: a 25-year follow-up study. Atherosclerosis. 1997;132(2):245–250.
   PubMed Web of Science ®Google Scholar
• Peeters MJ, van den Brand JA, van Zuilen AD, For the MASTERPLAN Study Group, et al. Abdominal aortic calcification in patients with CKD. J Nephrol. 2017;30(1):109–118.
   PubMed Web of Science ®Google Scholar
• Zeng J, Sauter ER, Li B. FABP4: a new player in obesity-associated breast cancer. Trends Mol Med. 2020;26(5):437–440.
   PubMed Web of Science ®Google Scholar
• Ota H, Furuhashi M, Ishimura S, et al. Elevation of fatty acid-binding protein 4 is predisposed by family history of hypertension and contributes to blood pressure elevation. Am J Hypertens. 2012;25(10):1124–1130.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Calvo R, Girona J, Rodríguez M, et al. Fatty acid binding protein 4 (FABP4) as a potential biomarker reflecting myocardial lipid storage in type 2 diabetes. Metabolism. 2019;96:12–21.
   PubMed Web of Science ®Google Scholar
• Trojnar M, Patro-Małysza J, Kimber-Trojnar Ż, et al. Associations between fatty acid-binding protein 4-a proinflammatory adipokine and insulin resistance, gestational and type 2 diabetes mellitus. Cells. 2019;8(3):227.
   Web of Science ®Google Scholar
• Furuhashi M, Sakuma I, Morimoto T, et al. Independent and distinct associations of FABP4 and FABP5 with metabolic parameters in type 2 diabetes mellitus. Front Endocrinol (Lausanne). 2020;11:575557.
   PubMed Web of Science ®Google Scholar
• Gormez S, Erdim R, Akan G, et al. Relationships between visceral/subcutaneous adipose tissue FABP4 expression and coronary atherosclerosis in patients with metabolic syndrome. Cardiovasc Pathol. 2020;46:107192.
   PubMed Web of Science ®Google Scholar
• Tuncman G, Erbay E, Hom X, et al. A genetic variant at the fatty acid-binding protein aP2 locus reduces the risk for hypertriglyceridemia, type 2 diabetes, and cardiovascular disease. Proc Natl Acad Sci U S A. 2006;103(18):6970–6975.
   PubMed Web of Science ®Google Scholar
• Sung CH, Hsu BG, Tasi JP, et al. Positive associations between adipocyte fatty acid-binding protein level and central arterial stiffness in peritoneal dialysis patients. Int J Hypertens. 2021;2021:8849115.
   PubMed Web of Science ®Google Scholar
• Tsai JP, Liou HH, Liu HM, et al. Fasting serum fatty acid-binding protein 4 level positively correlates with metabolic syndrome in hemodialysis patients. Arch Med Res. 2010;41(7):536–540.
   PubMed Web of Science ®Google Scholar
• Furuhashi M, Ishimura S, Ota H, et al. Serum fatty acid-binding protein 4 is a predictor of cardiovascular events in end-stage renal disease. PLoS One. 2011;6(11):e27356.
   PubMed Web of Science ®Google Scholar
• Furuhashi M, Fuseya T, Murata M, et al. Local production of fatty acid-binding protein 4 in epicardial/perivascular fat and macrophages is linked to coronary atherosclerosis. ATVB. 2016;36(5):825–834.
   Google Scholar
• Girona J, Rosales R, Plana N, et al. FABP4 induces vascular smooth muscle cell proliferation and migration through a MAPK-dependent pathway. PLoS One. 2013;8(11):e81914.
   PubMed Web of Science ®Google Scholar
• Aragonès G, Ferré R, Lázaro I, et al. Fatty acid-binding protein 4 is associated with endothelial dysfunction in patients with type 2 diabetes. Atherosclerosis. 2010;213(1):329–331.
   PubMed Web of Science ®Google Scholar
• Xu H, Hertzel AV, Steen KA, et al. Loss of fatty acid binding protein 4/aP2 reduces macrophage inflammation through activation of SIRT3. Mol Endocrinol. 2016;30(3):325–334.
   PubMedGoogle Scholar
• Xu H, Hertzel AV, Steen KA, et al. Uncoupling lipid metabolism from inflammation through fatty acid binding protein-dependent expression of UCP2. Mol Cell Biol. 2015;35(6):1055–1065.
   PubMed Web of Science ®Google Scholar
• Gan L, Liu Z, Cao W, et al. FABP4 reversed the regulation of leptin on mitochondrial fatty acid oxidation in mice adipocytes. Sci Rep. 2015;5:13588.
   PubMed Web of Science ®Google Scholar
• Peri-Okonny P, Baskin KK, Iwamoto G, et al. High-phosphate diet induces exercise intolerance and impairs fatty acid metabolism in mice. Circulation. 2019;139(11):1422–1434.
   PubMed Web of Science ®Google Scholar
• Dou HX, Wang T, Su HX, et al. Exogenous FABP4 interferes with differentiation, promotes lipolysis and inflammation in adipocytes. Endocrine. 2020;67(3):587–596.
   PubMed Web of Science ®Google Scholar
• Astudillo P, Ríos S, Pastenes L, et al. Increased adipogenesis of osteoporotic human-mesenchymal stem cells (MSCs) characterizes by impaired leptin action. J Cell Biochem. 2008;103(4):1054–1065.
   PubMed Web of Science ®Google Scholar
• Holloway WR, Collier FM, Aitken CJ, et al. Leptin inhibits osteoclast generation. J Bone Miner Res. 2002;17(2):200–209.
   PubMed Web of Science ®Google Scholar
• Tsuji K, Maeda T, Kawane T, et al. Leptin stimulates fibroblast growth factor 23 expression in bone and suppresses renal 1alpha,25-dihydroxyvitamin D3 synthesis in leptin-deficient mice. J Bone Miner Res. 2010;25(8):1711–1723.
   PubMed Web of Science ®Google Scholar
• Luo XH, Guo LJ, Xie H, et al. Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblasts through the MAPK signaling pathway. J Bone Miner Res. 2006;21(10):1648–1656.
   PubMed Web of Science ®Google Scholar